Other ongoing trials (Table 1) targeting CD8 are utilizing either [89Zr]Zr-Df-Crefmirlimab in stage III melanoma patients (NCT05289193), or [18F]F-GEH200521 in irresectable or metastatic solid tumors, or local and resectable head and neck squamous cell carcinomas. The gene discussed is CD8A; the disease is melanoma.